Promising liposarcoma drug trial halted early
NCT ID NCT05496569
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called TQB3616 for people with a rare type of fat tissue cancer called dedifferentiated liposarcoma that could not be removed by surgery. The goal was to see if the drug could slow down cancer growth compared to a placebo. The trial was stopped early and enrolled only 26 participants instead of the planned 118.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEDIFFERENTIATED LIPOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
-
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy boosts chemo against rare sarcomas?
- Could a breast cancer drug help fight liposarcoma?
- Drug combo shows promise in slowing rare sarcomas
- New drug combo targets Hard-to-Treat cancers in early trial
- Promising sarcoma combo study pulled before starting
- Experimental combo targets Hard-to-Treat bone cancer